Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion type Assertion NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_head.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion description "[We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion evidence source_evidence_literature NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion SIO_000772 25349305 NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion wasDerivedFrom befree-2016 NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.
- NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_assertion wasGeneratedBy ECO_0000203 NP1233057.RAf9Rn6iCXd2hcrRliTo9oYLYj5fnYSlyQx-dhlxFrG-I130_provenance.